Center for the Evaluation of Value and Risk in Health (CEVR)

What Center for the Evaluation of Value and Risk in Health (CEVR) does

The Center for the Evaluation of Value and Risk in Health (CEVR) is a research center housed within Tufts Medical Center's Institute for Clinical Research and Health Policy Studies in Boston, MA. Founded in 2006, CEVR builds and maintains three proprietary health economics databases: the CEA Registry (a comprehensive database of over 10,000 cost-utility analyses from 1976 to present, with standardized dual-reader data collection across 40+ variables per article), the Global Health CEA Registry (the first comprehensive database of cost-per-DALY averted articles, funded by the Bill and Melinda Gates Foundation), and the SPEC Database launched in 2018 (tracking 140,000+ specialty drug coverage decisions across 18 of the largest US commercial health plans, 475+ specialty drugs, and 430+ diseases). The organization employs 27 staff and is led by health economists Peter Neumann and Joshua Cohen, with a senior fellow bench that includes former CMS, ICER, and policy communications leaders. CEVR publishes extensively in peer-reviewed journals (JAMA, Health Affairs, Value in Health, JMCP, JCO Oncology Practice) and presents at ISPOR conferences globally.

CEVR monetizes primarily through tiered annual sponsorship subscriptions to its databases: Platinum at $65,000/year (pharma with marketed products, up to 6 symposium participants, full data downloads, priority researcher access), Gold at $25,000/year (pre-clinical or clinical-stage life sciences companies, 1 symposium participant), and Government/Academic/Non-Profit at $12,000/year. Additional revenue streams include $25,000 Value Framework Training Workshops (customizable half-day sessions on ICER methodology) and fee-based customized research analyses conducted by CEVR researchers. Named customers span major pharmaceutical companies (AbbVie, Pfizer, Novartis, J&J/Janssen, AstraZeneca, Eli Lilly, Gilead), UnitedHealth Group, the CDC, and the Canadian Cancer Society. Distribution is via direct institutional sales, secure online portals (cear.tuftsmedicalcenter.org and spec.tuftsmedicalcenter.org), and ISPOR membership benefits. The center maintains research independence with sole discretion over publication decisions regardless of sponsor views.

Name

Center for the Evaluation of Value and Risk in Health (CEVR)

Legal name

Center for the Evaluation of Value and Risk in Health at Tufts Medical Center

Website

https://cevr.tuftsmedicalcenter.org

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

CEVR is a Boston-based health economics research center within Tufts Medical Center that builds and licenses three proprietary databases (CEA Registry, GH CEA Registry, SPEC Database) and offers consulting to pharmaceutical companies, payers, government agencies, and academic institutions on cost-effectiveness analysis and specialty drug coverage policy.

Ownership category

akta.pro rank

Product category

Health Economics & Outcomes Research Databases

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Data Linkage, Registries & Longitudinal Cohort Surveillance (HLAJANAM)

akta.pro secondary industries

Health Data, Vital Statistics & Population Health Informatics (BPAIAJAM), Medication Pricing, Copay Assistance & Patient Financial Support Tools (HLACAKAN)

Keywords

• Health economics research
• Cost-effectiveness analysis
• Health outcomes databases
• Specialty drug coverage
• Health technology assessment

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Platinum Sponsorship: Annual sponsorship providing complete access to CEA Registry data, SPEC online portal access, annual training webinar, Tufts Medical Center Specialty Drug Coverage Trend Report, participation in CEVR Annual Methods, Policy, and Data symposium (up to 6 participants), priority access to CEVR researchers for customized fee-based analyses, and complete database download capabilities for statistical software analysis.
2. Gold Sponsorship: Annual sponsorship for pre-clinical or clinical stage pharmaceutical and life sciences companies without FDA-approved products on market. Provides same benefits as Platinum except limited to one participant at annual symposium.
3. Government, Academic, and Non-Profit Sponsorship: Annual fee for non-commercial use of CEA Registry data by government, academic, and non-profit organizations. Includes online search portal access to SPEC database for academic non-commercial use.
4. Value Framework Training Workshop: Interactive half-day workshop on value frameworks, focusing on Institute for Clinical and Economic Review (ICER) approach, conceptual limitations, and strategies for life sciences companies to maximize input influence. Customizable deep-dive format.
5. Customized Research Analysis: Fee-based customized analyses conducted by CEVR researchers for specific sponsor needs. Researchers available for priority engagement on custom analytical projects.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Core offering

CEVR develops and maintains three proprietary health economics databases—the CEA Registry (over 9,080 cost-utility analyses from 1976 to present), the Global Health CEA Registry (cost-per-DALY averted analyses funded by the Bill and Melinda Gates Foundation), and the SPEC Database (140,000+ coverage decisions from 18 major US commercial health plans for 475+ specialty drugs)—and sells subscription access through tiered institutional sponsorship packages to pharmaceutical companies, government agencies, and academic institutions. The organization supplements database access with fee-based customized research analyses and value framework training workshops covering ICER methodology.

Product overview

CEVR offers a suite of three complementary research databases focused on health economics and outcomes research. The core offering consists of the CEA Registry (comprehensive database of >10,000 cost-utility analyses published from 1976 to present), the Global Health CEA Registry (focused on cost-per-DALY averted analyses for global health interventions, funded by the Bill and Melinda Gates Foundation), and the SPEC Database (Specialty Drug Evidence and Coverage Database covering 18 large US commercial health plans, 475+ specialty drugs, and 140,000+ coverage decisions). Access to premium database content is provided through sponsorship programs (Platinum, Gold, Government/Academic/Non-Profit tiers).

Differentiator

Problem solved

Functional benefit

Brands

• CEA Registry: Cost-Effectiveness Analysis Registry - a comprehensive database of cost-utility analyses on diseases and treatments published from 1976 to present
• GH CEA Registry
• SPEC Database

Products and services

• Cost-Effectiveness Analysis (CEA) Registry A comprehensive database of over 9,080 cost-utility analyses on a wide variety of diseases and treatments published from 1976 to the present, measuring health benefits in terms of QALYs and DALYs. Used by researchers, policymakers, and institutional sponsors for health economic analysis. Data on over 40 variables is collected for each article using standardized forms and dual independent reader review.
• Global Health Cost Effectiveness Analysis (GH CEA) Registry The first comprehensive database compiling articles utilizing the cost-per-DALY averted metric to measure the efficacy of health interventions in countries at various stages of industrial development. Funded by the Bill and Melinda Gates Foundation, it serves global health researchers and policymakers analyzing intervention value in low-, middle-, and high-income countries.
• Specialty Drug Evidence and Coverage (SPEC) Database A database of US commercial health plans' coverage policies for specialty drugs, providing an empirical basis for understanding commercial payer specialty drug coverage. Contains data on 18 of the largest US commercial health plans representing approximately 70% of the market, 475+ specialty drugs, 140,000+ coverage decisions including historical decisions, and 430+ diseases including cancer, multiple sclerosis, rheumatoid arthritis, and rare diseases.
• Value Framework Training Workshop

Quantifiable outcome

• SPEC Database covers 18 of the largest US commercial health plans representing approximately 70% of the market
• +2 more outcomes

Named customers10 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered minor and core.

• argenxminorOthersargenx funded research on HEOR leaders survey including Tufts-CEVR HEOR Leaders Survey on Health Policy Challenges and Opportunities and Perspectives on Organizational Support and Evidence Opportunities. Research findings published to inform understanding of how industry HEOR departments adapt to healthcare environment changes.
• Tufts Medical CentercoreStrategic or Co-development PartnerCEVR is part of Tufts Medical Center's Institute for Clinical Research and Health Policy Studies (ICRHPS). The organization leverages the institutional relationship for research collaboration, faculty affiliations, and administrative infrastructure support.
• ISPORcoreStrategic or Co-development PartnerCEVR maintains a strong partnership with ISPOR through faculty presentations, poster sessions, and membership benefits. ISPOR student and LMIC members receive premium CEA Registry access as a membership benefit. CEVR faculty regularly participate in ISPOR panels, forums, workshops, and educational symposia.
• Institute for Clinical and Economic Review (ICER)minorOthersCEVR faculty member Dan Ollendorf holds dual affiliation as Chief Scientific Officer at ICER and Tufts Medical Center. CEVR offers Value Framework Training Workshop focusing on ICER methodology. Some CEVR sponsors include organizations that engage with ICER value assessments.
• Cure SMAminorStrategic or Co-development PartnerCEVR partnered with Cure SMA patient advocacy organization to recruit and survey parents of children who died from spinal muscular atrophy type 1 for bereavement research published in Value in Health and Journal of Pain and Symptom Management.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• IQVIA: IQVIA is a global health data and analytics incumbent with HEOR, real-world evidence, and market access capabilities. While much larger and broader than CEVR, IQVIA competes for pharma HEOR and payer data budgets and offers more API-integrated data infrastructure.
• Analysis Group: Analysis Group operates a large health economics consulting practice serving pharma, payers, and government. It competes for the same custom-research and economic-modeling engagements that CEVR addresses with its customized analysis service line.

Emerging players

• Truveta: Truveta is an emerging real-world health data platform aggregating de-identified EHR data from US health systems for pharma research. While currently focused on clinical RWE rather than cost-effectiveness, its API-first, AI-enabled model represents a potential future competitor to CEVR's portal-based research data model.

Direct peers

• RTI Health Solutions: RTI Health Solutions provides commercial HEOR, market access, and health economics research services to pharma and medtech. It competes for the same pharma HEOR budget CEVR addresses through its databases and custom research offerings.
• Evidera: Evidera (part of the PPD/Pharmaceutical Product Development business) is a commercial HEOR and market access research firm that sells evidence-generation and HTA-support services to pharma. Both CEVR and Evidera monetize pharma HEOR budgets through research and evidence synthesis.
• National Pharmaceutical Council (NPC): NPC conducts real-world evidence and HEOR research used by pharma and policymakers. CEVR researcher Jon Campbell is affiliated with NPC, and both organizations serve pharma HEOR buyers with similar evidence-generation and policy research offerings.
• Institute for Clinical and Economic Review (ICER): ICER is the most direct peer, performing cost-effectiveness analyses and value-based price benchmarks for US drugs and other interventions. CEVR and ICER collaborate closely (Ollendorf holds dual affiliation) and serve overlapping pharma, payer, and policymaker audiences with similar methodologies.
• Avalere Health: Avalere Health is a health policy and market access consultancy serving pharma, payers, and providers with evidence and policy analysis. It competes for the same policy research and market access advisory engagements that CEVR addresses through its customized research and policy seminar offerings.

Regional players

• NICE (National Institute for Health and Care Excellence): NICE is the UK's HTA body that performs cost-per-QALY-based assessments for NHS reimbursement. While CEVR aggregates CEAs globally, NICE produces them for policy decisions in a single (UK) jurisdiction, and both rely on the same QALY-based methodology CEVR curates in the CEA Registry.
• CADTH (Canadian Agency for Drugs and Technologies in Health): CADTH is Canada's national HTA body performing economic evaluations for public reimbursement. It operates in the same CEA/HTA methodology space as CEVR but for Canadian policy, paralleling how NICE serves the UK.

Market position

Strengths1 record

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cevr

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Center for the Evaluation of Value and Risk in Health (CEVR)